The Manufacturers Life Insurance Company increased its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 8.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,631 shares of the company’s stock after purchasing an additional 1,500 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.08% of Oxford Immunotec Global worth $313,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in OXFD. Voya Investment Management LLC grew its stake in Oxford Immunotec Global by 16.0% in the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after purchasing an additional 1,845 shares in the last quarter. Alliancebernstein L.P. bought a new position in Oxford Immunotec Global in the second quarter worth approximately $247,000. Rhumbline Advisers grew its stake in Oxford Immunotec Global by 9.1% in the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock worth $412,000 after purchasing an additional 2,053 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Oxford Immunotec Global by 175.0% in the first quarter. Goldman Sachs Group Inc. now owns 35,678 shares of the company’s stock worth $553,000 after purchasing an additional 22,704 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in Oxford Immunotec Global by 15.7% during the 1st quarter. Teachers Advisors LLC now owns 46,200 shares of the company’s stock valued at $716,000 after acquiring an additional 6,268 shares in the last quarter. 89.35% of the stock is currently owned by institutional investors.
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at $14.88 on Monday. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global PLC has a 52-week low of $12.19 and a 52-week high of $19.51.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the sale, the director now owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. 8.11% of the stock is currently owned by company insiders.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).
What are top analysts saying about Oxford Immunotec Global PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford Immunotec Global PLC and related companies.